Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up of Simeprevir-treated HCV Patients
NCT01349465Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2011
- Primary completion
- Jan 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Jul 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01349465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349465.